Journals / Turkish Journal of Pediatrics / 2020 / Cilt: 62 - Sayı: 3

Effect of long-term glucocorticoid therapy on bone mineral density of the patients with congenital adrenal hyperplasia

Pages
359–366
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Precautions should be taken for increased risk of obesity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and objectives.
📊
Key Findings & Data:This prospective case-control study was conducted in children, adolescents and young adults with classical 21-hydroxylase CAH, and age-, sex-, and pubertal stage matched healthy controls.
💡
Conclusion & Impact:Precautions should be taken for increased risk of obesity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background and objectives. Congenital adrenal hyperplasia (CAH) is characterized by androgen excess which should be treated with life-long glucocorticoid therapy, thus can affect bone mineralization. We aimed to evaluate the bone mineral density (BMD) and determine the factors affecting bone mineralization in patients with CAH. Method. This prospective case-control study was conducted in children, adolescents and young adults with classical 21-hydroxylase CAH, and age-, sex-, and pubertal stage matched healthy controls. Lumbar1-4 BMD was determined by dual-energy X-ray absorptiometry. BMD z-score was calculated using national standards with respect to height age and was referred as “low BMD” if z-score < -1 SD. Univariate analyses were performed between low BMD and normal BMD groups, and multivariate logistic regression analysis was performed to assess the independent predictors of low BMD. Correlations of Body Mass Index (BMI)-z-score, average serum 17-hydroxyprogesterone level, duration of treatment, average and cumulative glucocorticoid doses with BMD z-score were evaluated with Spearman analyses. Results. Each group included 37 cases. BMD z-score of patients with CAH [0.47 (-0.04 – 1.56)] was higher than control group [-0.43 (-0.82 –0.05)]; p= < 0.001. Number of patients with low BMD was similar in both groups; [CAH: 6(16.2%), control: 5(13.5%); p= 0.744]. BMI- z-score was higher in patients with CAH when compared to control group; p= < 0.001. BMI z-score was lower in low BMD group as comparison to normal BMD group; p= 0.041. Each 1.0 decrease in BMI z-score, risk of having low BMD was found to increase by 1.79 (%95 CI: 1.03-3.12, p= 0.040). BMI-z-score, average serum 17-hydroxyprogesterone level, duration of treatment, average and cumulative glucocorticoid doses were not found to be correlated with BMD z-score. Conclusion. Long-term glucocorticoid therapy did not have negative effect on BMD of patients with CAH. Higher BMI z-score in patients with CAH may have a positive effect on preserving bone health. Precautions should be taken for increased risk of obesity.

🔖

Cite This Article

ÜNAL, S., ALİKAŞİFOĞLU, A., OZON, A., GÖNÇ, N., KANDEMİR, N. (2020). Effect of long-term glucocorticoid therapy on bone mineral density of the patients with congenital adrenal hyperplasia. Turkish Journal of Pediatrics, Cilt: 62 - Sayı: 3, 359–366. https://ajindex.com/articles/411851

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788
  2. Chakhtoura Z, Bachelot A, Samara-Boustani D, et al; Centre des Maladies Endocriniennes Rares de la Croissance and Association Surrénales. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2008; 158: 879-887
  3. Arisaka O, Hoshi M, Kanazawa S, et al. Preliminary report: effect of adrenal androgen and estrogen on bone maturation and bone mineral density. Metabolism 2001; 50: 377-379
  4. Ceccato F, Barbot M, Albiger N, et al. Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2016; 175: 101-106
  5. Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012; 97: 85-92
  6. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997; 82: 3926-3929
  7. Gussinye M, Carrascosa A, Potau N, et al. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997; 100: 671-674
  8. Elnecave RH, Kopacek C, Rigatto M, Keller Brenner J, Sisson de Castro JA. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency. J Pediatr Endocrinol Metab 2008; 21: 1155-1162
  9. Cetinkaya S, Kara C. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2011; 24: 265-269
  10. Okten A, Cakir M, Makuloglu M. Bone mineral status, bone turnover markers and vitamin D status in children with congenital adrenal hyperplasia. Minerva Endocrinol 2012; 37: 275-282
  11. Ganesh R, Suresh N, Janakiraman L. Bone mineral content and density in Indian children with congenital adrenal hyperplasia. Indian Pediatr 2018; 55: 880-882
  12. Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S. Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res 2000; 54: 164-168. 13. de Almeida Freire PO, de Lemos-Marini SH, Maciel- Guerra AT, et al. Classical congenital adrenal hyperplasia due to 21-hydrox